Judge orders a halt to Alzheimer's spat as Eli Lilly chooses sides in dispute
August 5, 2015 | By Damian Garde 
A California judge has stepped between two top research institutions fighting over a vast Alzheimer's disease R&D program with ties to Big Pharma, ordering the study's new managers to hand it back for the time being. The ruling came the same day Eli Lilly publicly sided with USC and Paul Aisen, the former UC San Diego researcher who has played a central role in the continued development of the Phase III drug solanezumab, in the dispute./;;;/
No comments:
Post a Comment